25
OCT
2017
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
Comments : Off
3 Cases Substantially Completed, 4th Case Pending Completion, No Monetary Damages Contemplated Bethesda, MD, October 24, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company’s... Read More